Detecting and removing high-risk adenomas and early colorectal cancer (CRC) can reduce
mortality of this disease. The noninvasive fecal occult blood test (FOBT; guaiac-based or
immunochemical) is widely used in screening programs and although effective, it leaves
room for improvement in terms of test accuracy. Molecular tests are expected to be more
sensitive, specific and informative than current detection tests, and are promising future tools
for CRC screening. This review provides an overview of the performances of DNA, RNA, and …